Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: Correlation with the clinical parameters

Clinical and Experimental Immunology

Volumn 107, Issue 1, 1997, Pages 175-181

  Takizawa, H ^a   Satoh, M ^a   Okazaki, H ^a   Matsuzaki, G ^a   Suzuki, N ^a   Ishii, A ^a   Suko, M ^a   Okudaira, H ^a   Morita, Y ^a   Ito, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bronchoalveolar lavage; IL 6; IL 8; Sarcoidosis

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; PREDNISOLONE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG LAVAGE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOIDOSIS;

EID: 8044226590     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-905.x     Document Type: Article

References (27)

1. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1990; 135:747-60.
2. Bachwich PR, Lynch III JP, Larrick J et al. Tumor necrosis factor production by human sarcoidosis alveolar macrophages. Am J Pathol 1986; 125:421-5.
3. Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1984; 129:569-72.
4. Yamaguchi E, Okazaki N, Tsuneta Y et al. Interleukins in pulmonary sarcoidosis: dissociative correlation of lung interleukins 1 and 2 with the intensity of alveolitis. Am Rev Respir Dis 1988; 138:645-51.
5. Hirano T, Yasukawa K, Harada T et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (London) 1986; 324:73-76.
6. Lotz M, Jirik F, Kabouridis P et al. B cell stimulatory factor/inlerleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988; 167:1253-8.
7. Horii Y, Muraguchi A, Suematsu S et al. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol 1988; 141:1529-35.
8. Helfgott DC, May LT, Sthoeger Z et al. Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 Interferon by human fibroblasts. J Exp Med 1987; 166:1300-9.
9. Norioka K, Hara M, Harigai M et al. Production of B cell stimulatory-2/ interleukin-6 activity by human endothelial cells. Biochem Biophys Res Commun 1988; 153:1045-50.
10. Hirano T, Kishimoto T. Interleukin-6. Peptide growth factors and their receptors. In: Sporn MB, Roberts AB, (eds. Handbook of experimental pharmacology, Vol. 95/I. Berlin:Springer Verlag, 1990: 634-65.
11. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1993; 55:97-179.
12. Larsen CG, Anderson AO, Appella E et al. The neutrophil activating protein (NAP-1) is also chemotactic for T-lymphocytes. Science 1989; 243:1464-6.
13. Larsen CG, Thomsen MK, Gesser B et al. The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. J Immunol 1995; 155:2151-7.
14. Steffen M, Peterson J, Oldigs M et al. Increased secretion of TNFalpha, IL-1 beta and IL-6 by alveolar macrophages from pateints with sarcoidosis. J Allergy Clin Immunol 1993; 91:939-49.
15. Car BD, Meloni F, Luisetti M et al. Elevated IL-8 and MCP-1 in BAL fluid of patients with IPF and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149:655-9.
16. Girgis RE, Basha MA, Maliarik M et al. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 152:71-75.
17. Jones KP, Reynolds SP, Capper SJ et al. Measurement of interleukin-6 in bronchoalveolar lavage fluid by radioimmunoassay:differences between patients with interstitial lung diseases and control subjects. Clin Exp Immunol 1991: 83:30-34.
18. Sarcoidosis. In: Fraser RG, Paré JAP, Paré PD et al., eds. The diagnosis of disease of the chest. Philadelphia: Saunders, 1991:2611.
19. Crystal RG, Bitterman PB, Rennard SI et al. Interstitial lung disease of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310:154-66.
20. Subcommittee for Scleoderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1984; 23:581-90.
21. Hunninghake GW, Gadek JE, Lawley TJ et al. Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1981; 68:259-69.
22. Matsuda T, Hirano T, Kishimoto T. Establishment of interleukin-6 (IL-6)/B cell stimulatory factor 2 (BSF-2)-dependent cell line and preparations of anti-IL-6/BSF-2 monoclonal antibodies. Eur J Immunol 1988; 18:951-6.
23. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33:644-9.
24. Robbins RA, Shoji S, Linder J, Gossman GZ, Allington LA, Classen LW, Rennard SI. Bronchial epithelial cells release chemotactic activity for lymphocytes. Am J Physiol 1989; 257:L109-15.
25. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305:429-34.
26. Bost TW, Riches DWH, Schumacher B et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am J Respir Cell Mol Biol 1994; 10:506-13.
27. Sahashi K, Ina Y, Takada K et al. Significance of interleukin 6 in patients with sarcoidosis. Chest 1994; 106:156-60.